Adenovirus vectors for gene delivery

Current Opinion in Biotechnology

Volumn 10, Issue 5, 1999, Pages 440-447

  Benihoud, Karim ^a   Yeh, Patrice ^a   Perricaudet, Michel ^a  

^a UMR1582 CNRS Rhone Poulenc G   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADENOVIRUS; CELLULAR IMMUNITY; CLONING VECTOR; GENE EXPRESSION; GENE TARGETING; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; PLANT GROWTH; PRIORITY JOURNAL; REVIEW; TRANSGENE;

EID: 0032834927     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(99)00007-5     Document Type: Review

References (63)

1. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1997;1320-1323.
2. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest. 90:1992;626-630.
3. Ketner G, Spencer F, Tugendreich S, Connelly C, Hieter P Efficient manipulation of the adenovirus genome as an infectious yeast artificial chromosome clone. Proc Natl Acad Sci USA. 91:1994;6186-6190.
4. Chartier C, Degryse E, Gintzer M, Dieterlé A, Pavirani P, Mehtali M Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 70:1996;4805-4810.
5. Crouzet J, Naudin L, Orsini C, Vigne E, Ferrero L, Le Roux A, Benoit P, Latta M, Torrent C, Branellec Det al. Recombinational construction in Eschechia coli of infectious adenoviral genomes. Proc Natl Acad Sci USA. 94:1997;1414-1419.
6. Hehir KM, Armentano D, Cardoza LM, Choquette TL, Berthelette PB, White GA, Couture LA, Everton MB, Keegan J, Martin JMet al. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurence. J Virol. 70:1996;8459-8467.
7. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan EJ, Auger C, Cramer SJ, van Ormondt H, van der Erb AJet al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 9:1998;1909-1917. To circumvent the formation of replication-competent adenoviruses (RCAs) during amplification in E1 complementing cell lines, a new complementing cell line PER.C6 containing Ad5 nucleotides 459-3510 was established. Propagation in this cell line of matched Ad vectors that lack these same Ad5 nucleotides leads to the undetectable generation of RCAs.
8. Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud J-M, Aubailly N, Orsini C, Guillaume J-M Opolon Pet al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol. 71:1997;4626-4637.
9. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM Cellular and humoral responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long term expression. Proc Natl Acad Sci USA. 92:1995;1401-1405.
10. Moore M, Horikoshi N, Shenk T Oncogenic potential of the adenovirus E4orf6 protein. Proc Natl Acad Sci USA. 93:1996;11295-11301.
11. Gao GP, Yang Y, Wilson JM Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 70:1996;8934-8943.
12. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH Persistent transgene expression in mouse liver following in vivo gene transfer with a Δ E1/Δ E4 adenovirus vector. Gene Ther. 4:1997;393-400.
13. Chirmule N, Hughes JW, Gao GP, Raper SE, Wilson JM Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol. 72:1998;6138-6145.
14. Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, Mourot B, Schultz H, Stoeckel F, Pavirani A, Mehtali M In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol. 72:1998;2022-2032. This study was designed to unravel precisely the importance of an E2A or an E4 deletion in the persistence of Ad genome lacking transgenes to avoid side immunological effects linked to the transgene product. Whatever the deletion, however, the in vivo persistence of the transduced cells is not extended compared with E1-deleted virus, thereby minimizing the role of cellular immunity to viral antigens.
15. Kaplan JM, Armentano D, Scaria A, Woodworth LA, Pennington SE, Wadsworth SC, Smith AE, Gregory RJ Novel role for E4 region in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes. J Virol. 73:1999;4489-4492.
16. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS Production and characterization of improved adenovirus vectors with the E1, E2b and E3 genes deleted. J Virol. 72:1998;926-933. This study reports that deletion of E1 and E2b (polymerase) genes leads to a block in Ad replication along with a reduction of Ad late gene expression compared with E1-deleted Ad.
17. Moorhead JW, Clayton GH, Smith RL, Schaack J A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. J Virol. 73:1999;1046-1053.
18. Hu H, Serra D, Amalfitano A Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther. 10:1999;355-364.
19. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA. 93:1996;5731-5736.
20. Clemens P, Kochanek S, Sunada Y, Chan S, Chen HH, Campbell KP, Caskey CT In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3:1996;965-972.
21. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA. 94:1997;1645-1650.
22. Morsy MA, Gu MC, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FLet al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA. 95:1998;7866-7871.
23. Schiedner G, Morral N, Parks RJ, Wu J, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 18:1998;180-183. This study reports that a gutless Ad containing the complete human α1-antitrypsin locus was able to achieve a tissue-specific expression for more than 10 months. Such a long expression could be related to the presence within the viral genome of a matrix-association region.
24. Lieber A, He CY, Kirillova I, Kay MA Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol. 70:1996;8944-8960.
25. Lieber A, He CY, Kay MA Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotechnol. 15:1997;1383-1387.
26. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA. 95:1998;11377-11382. This paper reports that in vivo injection of a biologically inactive E1-deleted Ad leads to CTL induction. This observation demonstrated that a strong cellular response arose without de novo synthesis of either viral or transgene products, most probably because of the ability of viral particle proteins to enter the MHC-class I processing pathway. This study underlines the fact that even gutless vectors will not completely abrogate the host immune response and demonstrates the necessity of controling the immune system induction at the time of Ad injection.
27. Kovesdi I, Brough DE, Bruder JT, Wickham TJ Adenoviral vectors for gene transfer. Curr Opin Biotechnol. 8:1997;583-589.
28. Bramson JL, Hitt M, Gauldie J, Graham FL Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4:1997;1069-1076.
29. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol. 70:1996;6370-6377.
30. Yang Y, Trinchieri G, Wilson JM Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med. 1:1995;890-893.
31. Qin L, Ding Y, Pahud DR, Robson ND, Shaked A, Bromberg JS Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther. 8:1997;1365-1374.
32. Bruder JT, Jie T, McVey DL, Kovesdi I Expression of gp19k increases the persistence of transgene expression from an adenovirus vector in the mouse lung. J Virol. 71:1997;7623-7628.
33. 3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther. 2:1995;1-7.
34. Roy S, Shirley PS, McClelland A, Kaleko M Circumvention of immunity to the adenovirus major coat protein hexon. J Virol. 72:1998;6875-6879. The authors propose to replace part of the Ad5 hexon by the hexon of a virus serotype that only rarely leads to human infection. Such a hexon-replacement strategy may overcome the problem that arises from the pre-existence of anti-Ad5 neutralizing antibodies.
35. Gahéry-Ségard H, Farace F, Godfrin D, Gaston J, Lengagne R, Tursz T, Boulanger P, Guillet JG Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol. 72:1998;2388-2397. These results indicate that in humans anti-Ad neutralizing activity is obtained with sera containing both anti-fiber and anti-penton antibodies.
36. Ginsberg HS, Moldawer LL, Sehgal P, Redington M, Kilian PL, Chanock RM, Prince GA A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA. 88:1991;1651-1655.
37. Shisler J, Yang C, Walter B, Ware CF, Gooding LR The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface (CD95) and resistance to Fas-induced apoptosis. J Virol. 71:1997;8299-8306.
38. Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, Toth K, Wells CE, Doherty PC, Wold WSM Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature. 392:1998;726-729.
39. Chen P, Tian J, Kovesdi I, Bruder JT Interaction of the adenovirus 14.7 kDa protein with FLICE inhibits Fas Ligand-induced apoptosis. J Biol Chem. 273:1998;5815-5820. This is the first demonstration that the E3-14.7 kDa protein binds to the effector caspase 8 common to both TNFR and Fas-apoptosis pathways. Previous studies involving the 14.7 kDa protein in the blocking of cPLA2 translocation should be reconsidered if the exact relationship between cPLA2 and caspases is to be unraveled.
40. Ginsberg HS, Lundholm-Beauchamp U, Horswood RL, Pernis B, Wold WSM, Chanock RM, Prince GA Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA. 86:1989;3823-3827.
41. Sparer TE, Tripp RA, Dillehay DL, Hermiston TW, Wold WS, Gooding LR The role of human adenovirus early region 3 proteins (gp19k, 10.4K, 14.5K and 14.7K) in a murine pneumonia model. J Virol. 70:1996;2431-2439.
42. Elkon KB, Liu CC, Gall JG, Trevejo J, Marino MW, Abrahamsen KA, Song X, Zhou JL, Old LJ, Crystal RG, Falck-Pedersen E Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA. 94:1997;9814-9819.
43. Benihoud K, Saggio I, Opolon P, Salone B, Amiot F, Connault E, Chianale C, Dautry F, Yeh P, Perricaudet M Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin a. J Virol. 72:1998;9514-9525. This paper demonstrates a crucial role of TNF-α in mounting an anti-Ad immune response. Furthermore, the reduced immune response observed in heterozygous mice expressing intermediate levels of TNF-α strongly suggests that blocking TNF-α in normal mice would lead to a reduction in the TNF-α mediated immune response.
44. Zhang HG, Zhou T, Yang P, Edwards CK III, Curiel DT, Mountz DM Inhibition of tumor necrosis factor α decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther. 9:1998;1875-1884. Using a soluble TNFR to inhibit TNF-α, the authors showed that this cytokine drives the inflammatory responses following Ad gene transfer in both liver and lung.
45. Peng Y, Trevejo J, Zhou J, Marino MW, Crystal RG, Falck-Pedersen E, Elkon KB Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J Virol. 73:1999;5098-5109. A soluble Ad-encoded TNF-α receptor extends transgene expression by reducing the infiltration of mononuclear cells. The lack of TNF-α signaling does not impair T lymphocyte proliferation; however, a moderate reduction in the anti-Ad humoral response was achieved.
46. Ilan Y, Droguett G, Roy Chowdhury N, Li Y, Sengupta K, Thummala NR, Davidson A, Roy Chowdhury J, Horwitz MS Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA. 94:1997;2587-2592.
47. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA Adenovirus type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 16:1997;2294-2306.
48. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 14:1996;1574-1578.
49. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58:1998;5738-5748.
50. Wickham TJ, Tzeng E, Shears LL II, Roelvink PW, Li Y, Lee GM, Brough DE, Lizonova A, Kovesdi I Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 71:1997;8221-8229.
51. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechol. 14:1996;1570-1573.
52. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a Coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 72:1998;9706-9713. This paper demonstrates that incorporation of an RGD motif in the HI loop of the fiber knob provides the virus with a new entry process via cellular integrins.
53. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol. 73:1999;5156-5161. Although hexon has never been implicated in adenovirus entry, hexon-modified capsids increased the transduction efficiency of cells naturally refractory to adenovirus infection.
54. Douglas JT, Miller CR, Kim M, Dimitriev I, Mikheeva G, Krasnykh V, Curiel DT A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol. 17:1999;470-475. Matched engineering of both the vector and the complementing cell line to express a particular ligand and its specific receptor, respectively, provides new tools to construct and propagate truly retargeted viruses that no longer bind to CAR.
55. Jooss K, Yang Y, Fisher KJ, Wilson JM Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol. 72:1998;4212-4223.
56. Armentano D, Zabner J, Sacks C, Sookdeo CC, Smith MP, St George JA, Wadsworth SC, Smith AE, Gregory RJ Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol. 71:1997;2408-2416.
57. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA. 96:1999;355-360. This paper reports the use of a gutless Ad encoding both a chimeric transactivator and a target gene containing a binding sequence for the transactivator to obtain ligand-inducible transactivation of the target gene. Furthermore, coupling the transactivator to a liver-specific promoter achieves tissue-specific expression of the target gene.
58. Griscelli F, Gilardi-Hebenstreit P, Hanania N, Franz WM, Opolon P, Perricaudet M, Ragot T Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors. Hum Gene Ther. 9:1998;1919-1928.
59. Molin M, Shoshan MC, Öhman-Forslund K, Linder S, Akusjarvi G Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments. J Virol. 72:1998;8358-8361.
60. Corti O, Sabaté O, Horellou P, Colin P, Dumas S, Buchet D, Buc-Caron M-H, Mallet J A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nat Biotechnol. 17:1999;349-354.
61. Harding TC, Geddes BJ, Murphy D, Knight D, Uney JB Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol. 16:1998;553-555.
62. Feng M, Jackson WH, Goldman CK, Rancourt C, Wang M, Dusing SK, Siegal G, Curiel DT Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol. 15:1997;866-870.
63. Recchia A, Parks RJ, Lamartina S, Toniatti C, Pieroni L, Palombo F, Ciliberto G, Graham FL, Cortese R, La Monica N, Colloca S Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA. 96:1999;2615-2620. This paper reports in vitro data showing that the AAV Rep protein encoded by a first adenovirus can drive the insertion of a transgene delivered from a second adenovirus into chromosome 19. This strategy may be applied to extend transgene expression following Ad-mediated delivery.